Carcinomas News and Research

RSS

New discovery reveals which patients will survive longer after receiving immunotherapy

Patients with head and neck cancer who have more genetic material on chromosome 9 in their cancer cells survive three times longer after receiving immunotherapy than those with less genetic material there, a new study finds.

14 Nov 2022

Researchers focus on the identification of markers to improve head and neck cancer risk assessment

Malignant tumors in the head and neck region are very heterogeneous and therefore difficult to treat. In addition, the lack of prognostic markers is a significant impediment to personalized treatment.

25 Oct 2022

Signal transduction via the EGFR pathway likely to be involved in lenvatinib resistance

The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become resistant to lenvatinib remain poorly understood. In this study, we demonstrated, for the first time, that activation of the epidermal growth factor receptor (EGFR)-mediated signaling pathway is involved in lenvatinib resistance in thyroid cancer cells.

14 Sep 2022

Pollutant particles in the air trigger lung cancer in non-smokers

A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and development of therapies, according to late-breaking data [to be] reported at the ESMO Congress 2022 by scientists of the Francis Crick Institute and University College London, funded by Cancer Research UK. The particles, which are typically found in vehicle exhaust and smoke from fossil fuels, are associated with non-small cell lung cancer (NSCLC) risk, accounting for over 250,000 lung cancer deaths globally per year.

12 Sep 2022

Scientists identify new driver for rare type of liver cancer

Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Hebrew University in Jerusalem have identified in mice the cell of origin of combined liver/biliary duct carcinomas, a rare type of cancer of the liver.

19 Aug 2022

Nutritive intervention could be an effective treatment method in maintaining human health

In a new study, researchers assessed the impact of dietary regulation on human health and disease.

1 Aug 2022

Lung cancer patients treated with immune checkpoint inhibitors can be safely vaccinated against COVID-19, study says

Cancer patients have received priority status to receive COVID-19 vaccinations but there is limited data regarding the safety and efficacy of the vaccines for patients treated for lung cancer with immune checkpoint inhibitors.

22 Jun 2022

First-in-class, anti-cancer mitochondrial drug found to be effective against most carcinoma cell lines

A study of the lead agent (CPI-613) in a class of anticancer drugs undergoing Food and Drug Administration (FDA) approved clinical trials reveals that CPI-613 is effective against most carcinoma cell lines, and, used in combination, could have efficacy against reducing some tumors.

9 Jun 2022

New initiative aims to increase collaboration and accelerate high-impact cancer immunotherapy

The accelerated advancement of cancer immunology and immunotherapy, a type of biological therapy that boosts the immune system's ability to recognize and kill cancer cells, has significantly improved the effectiveness of cancer treatment and patient outcomes.

25 May 2022

Penn study finds low uptake of first mutation-targeted bladder cancer drug

The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

12 May 2022

New therapeutic option for HPV-positive head and neck carcinoma discovered

The various manifestations of head and neck carcinomas rank sixth in frequency worldwide and are fatal for about half a million people every year. In a quarter of cases, head and neck squamous cell carcinoma (HNSCC) is caused by human papillomavirus (HPV) and, currently, is not always treatable.

19 Apr 2022

Study identifies several therapeutically effective drugs for bladder cancer

Hundreds of chemical compounds were screened on cell cultures representing different stages and subtypes of bladder cancer and several promising agents with inhibitory (growth-inhibiting) effects were identified.

11 Apr 2022

Creation of immunosuppressive environment is key to the progression of colorectal cancer development

Interactions between cells of the immune system and pre-cancerous cells are known to be important contributing factors to the initiation and progression of cancer.

7 Apr 2022

Mayo Clinic researchers report differences in genomic data quality among racial groups

Mayo Clinic researchers studied the differences in genomic data quality among racial groups in one of the largest and most widely used cancer research datasets, The Cancer Genome Atlas.

17 Mar 2022

Salk professors receive $3 million Endeavor Award to support lung cancer research

Professors Reuben Shaw, Susan Kaech, Christian Metallo and Alan Saghatelian have received a 2022 Mark Foundation for Cancer Research Endeavor Award to support their research exploring the metabolic changes that help lung cancers develop.

11 Mar 2022

Merkel cell carcinoma has a higher post-treatment recurrence rate than other skin cancers

Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40% - markedly higher than the recurrence rates for melanoma and other skin cancers, according to research published today in JAMA Dermatology.

23 Feb 2022

Codiak's publication highlights the ability of exoASO-STAT6 to selectively target tumor-associated macrophages

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a new manuscript, Exosome mediated genetic reprogramming of tumor associated macrophages by exoASO-STAT6 leads to potent monotherapy anti-tumor efficacy, in the American Association for the Advancement of Science's journal, Science Advances.

18 Feb 2022